AviadoBio Ltd. | MedPath

Astellas and AviadoBio Partner in $2.2 Billion Deal to Advance Gene Therapy for Frontotemporal Dementia

8 months ago

• Astellas Pharma and AviadoBio have entered into an agreement potentially worth $2.2 billion to advance AVB-101, a gene therapy for frontotemporal dementia with progranulin mutations (FTD-GRN). • AVB-101 is currently in Phase I/II development and aims to restore progranulin levels in the brain via a one-time, targeted delivery. • The collaboration includes an upfront payment and equity investment from Astellas, with potential milestone payments and royalties upon exercising the license option. • Frontotemporal dementia is a devastating early-onset dementia with no current cure, highlighting the urgent need for new treatments like AVB-101.